(TDOC) Teladoc - Overview
Sector: Healthcare | Industry: Health Information Services | Exchange: NYSE (USA) | Market Cap: 1.262m USD | Total Return: 10.8% in 12m
Avg Turnover: 29.0M
Qual. Beats: 1
Rev. Trend: -60.6%
Qual. Beats: 0
Warnings
Interest Coverage Ratio -8.8 is critical
Altman Z'' -15.00 < 1.0 - financial distress zone
Fakeout Extended 1w
Tailwinds
Idiosyncratic Leader
Teladoc Health, Inc. (TDOC) is a multinational virtual healthcare provider operating through two primary segments: Integrated Care and BetterHelp. The Integrated Care division delivers a broad spectrum of clinical services, including chronic condition management and specialty medical consultations, targeted at enterprise clients such as employers and health systems. The BetterHelp segment focuses on direct-to-consumer mental health services, utilizing a digital platform to connect licensed clinicians with individuals via various telecommunication channels.
The company operates within the Health Care Technology sector, a field characterized by high capital expenditures related to software development and data security compliance. Teladoc utilizes a B2B2C business model for its integrated services, generating revenue through per-member-per-month subscription fees and visit-based charges. This diversified approach allows the firm to capture value from both institutional contracts and individual consumer demand for remote therapy.
For more detailed fundamental analysis, consider exploring the data available on ValueRay. Teladoc’s strategic shift in 2018 reflected an expansion from simple urgent care visits to a holistic whole-person virtual care strategy.
- BetterHelp advertising spend volatility impacts customer acquisition costs and operating margins
- Chronic condition management enrollment growth drives long-term recurring revenue stability
- Competitive pricing pressure from integrated health insurers reduces enterprise contract margins
- High interest rates increase debt servicing costs for historical acquisition financing
- Direct-to-consumer mental health demand fluctuations influence quarterly revenue performance targets
| Net Income: -171.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 2.95 > 1.0 |
| NWC/Revenue: 28.93% < 20% (prev 25.44%; Δ 3.49% < -1%) |
| CFO/TA 0.10 > 3% & CFO 288.0m > Net Income -171.1m |
| Net Debt (319.1m) to EBITDA (64.1m): 4.98 < 3 |
| Current Ratio: 2.80 > 1.5 & < 3 |
| Outstanding Shares: last quarter (179.1m) vs 12m ago 2.85% < -2% |
| Gross Margin: 65.62% > 18% (prev 0.70%; Δ 6.49k% > 0.5%) |
| Asset Turnover: 80.44% > 50% (prev 74.11%; Δ 6.33% > 0%) |
| Interest Coverage Ratio: -8.76 > 6 (EBITDA TTM 64.1m / Interest Expense TTM 19.3m) |
| A: 0.26 (Total Current Assets 1.13b - Total Current Liabilities 404.9m) / Total Assets 2.81b |
| B: -5.88 (Retained Earnings -16.5b / Total Assets 2.81b) |
| C: -0.05 (EBIT TTM -169.1m / Avg Total Assets 3.13b) |
| D: -11.24 (Book Value of Equity -16.5b / Total Liabilities 1.47b) |
| Altman-Z'' = -29.62 = D |
| DSRI: 0.89 (Receivables 213.6m/243.2m, Revenue 2.51b/2.55b) |
| GMI: 1.07 (GM 65.62% / 70.48%) |
| AQI: 1.12 (AQ_t 0.58 / AQ_t-1 0.52) |
| SGI: 0.98 (Revenue 2.51b / 2.55b) |
| TATA: -0.16 (NI -171.1m - CFO 288.0m) / TA 2.81b) |
| Beneish M = -3.16 (Cap -4..+1) = AA |
As of June 01, 2026, the stock is trading at USD 7.61 with a total of 6,412,112 shares traded.
Over the past week, the price has changed by +15.83%,
over one month by +25.58%,
over three months by +47.48% and
over the past year by +10.77%.
Teladoc has received a consensus analysts rating of 3.33. Therefore, it is recommended to hold TDOC.
- StrongBuy: 3
- Buy: 2
- Hold: 19
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 7.2 | -5.5% |
P/E Forward = 303.0303
P/S = 0.5018
P/B = 0.8902
P/EG = -1.01
Revenue TTM = 2.51b USD
EBIT TTM = -169.1m USD
EBITDA TTM = 64.1m USD
Long Term Debt = 995.8m USD (from longTermDebt, last quarter)
Short Term Debt = 11.0m USD (from shortTermDebt, last fiscal year)
Debt = 1.07b USD (from shortLongTermDebtTotal, last quarter) + Leases 42.2m
Net Debt = 319.1m USD (calculated: Debt 1.07b - CCE 750.7m)
Enterprise Value = 1.58b USD (1.26b + Debt 1.07b - CCE 750.7m)
Interest Coverage Ratio = -8.76 (Ebit TTM -169.1m / Interest Expense TTM 19.3m)
EV/FCF = 6.30x (Enterprise Value 1.58b / FCF TTM 251.1m)
FCF Yield = 15.88% (FCF TTM 251.1m / Enterprise Value 1.58b)
FCF Margin = 9.99% (FCF TTM 251.1m / Revenue TTM 2.51b)
Net Margin = -6.81% (Net Income TTM -171.1m / Revenue TTM 2.51b)
Gross Margin = 65.62% ((Revenue TTM 2.51b - Cost of Revenue TTM 864.6m) / Revenue TTM)
Gross Margin QoQ = 52.79% (prev 69.32%)
Tobins Q-Ratio = 0.56 (Enterprise Value 1.58b / Total Assets 2.81b)
Interest Expense / Debt = 1.81% (Interest Expense 19.3m / Debt 1.07b)
Taxrate = 21.0% (US default 21%)
NOPAT = -133.6m (EBIT -169.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.80 (Total Current Assets 1.13b / Total Current Liabilities 404.9m)
Debt / Equity = 0.80 (Debt 1.07b / totalStockholderEquity, last quarter 1.34b)
Debt / EBITDA = 4.98 (Net Debt 319.1m / EBITDA 64.1m)
Debt / FCF = 1.27 (Net Debt 319.1m / FCF TTM 251.1m)
Total Stockholder Equity = 1.38b (last 4 quarters mean from totalStockholderEquity)
RoA = -5.48% (Net Income -171.1m / Total Assets 2.81b)
RoE = -0.96% (Net Income TTM -171.1m / Total Stockholder Equity 17.9b)
RoCE = -0.90% (EBIT -169.1m / Capital Employed (Equity 17.9b + L.T.Debt 995.8m))
RoIC = -5.54% (negative operating profit) (NOPAT -133.6m / Invested Capital 2.41b)
WACC = 7.67% (E(1.26b)/V(2.33b) * Re(12.96%) + D(1.07b)/V(2.33b) * Rd(1.81%) * (1-Tc(0.21)))
Discount Rate = 12.96% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 3.42%
[DCF] Terminal Value 77.97% ; FCFF base≈233.2m ; Y1≈267.3m ; Y5≈393.4m
[DCF] Fair Price = 31.03 (EV 5.92b - Net Debt 319.1m = Equity 5.60b / Shares 180.5m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.98 | # QB: 1
Revenue Correlation: -60.63 | Revenue CAGR: -0.93% | SUE: 0.40 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.24 | Chg30d=-6.00% | Revisions=-33% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-0.17 | Chg30d=+7.18% | Revisions=+20% | Analysts=3
EPS current Year (2026-12-31): EPS=-0.79 | Chg30d=+16.22% | Revisions=+14% | GrowthEPS=-20.0% | GrowthRev=-1.0%
EPS next Year (2027-12-31): EPS=-0.65 | Chg30d=+30.62% | Revisions=+33% | GrowthEPS=+17.8% | GrowthRev=+1.3%
[Analyst] Revisions Ratio: -33%